<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37972000</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Potential drug-drug interactions of frequently prescribed medications in long COVID detected by two electronic databases.</ArticleTitle><Pagination><StartPage>e0293866</StartPage><MedlinePgn>e0293866</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0293866</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0293866</ELocationID><Abstract><AbstractText>Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a wide range of acute and chronic complications including long COVID, a well-known chronic sequela. Long COVID often necessitates long-term treatment, which may lead to an increased potential for drug-drug interactions (DDIs). The objective of this study was to assess potential DDIs among frequently prescribed medications in long COVID by using two electronic databases. Sixty frequently prescribed agents were selected from Thailand's National List of Essential Medicine 2022 for potential DDI analysis by Micromedex and Drugs.com. From these databases, 488 potential DDIs were identified. There were 271 and 434 DDI pairs based on Micromedex and Drugs.com, respectively. Among these DDIs, 77 pairs were labeled as contraindicated or major by both databases. The most common mechanisms for these serious interactions are cytochrome P450 (CYP) inhibition (45%), CYP induction (19%), and QT interval prolongation (7.8%). Based on Fleiss' kappa (0.073), there was only slight agreement of the DDI severity classifications between these two databases. In conclusion, a large number of potential DDIs were detected among frequently prescribed medications for long COVID. Health care providers should be aware of these DDIs, particularly those that are deemed as contraindicated or major. These DDIs are most likely to cause significant adverse events in patients with long COVID because polypharmacy is common.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Meakleartmongkol et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meakleartmongkol</LastName><ForeName>Theejutha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tangpanithandee</LastName><ForeName>Supawit</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6103-2338</Identifier><AffiliationInfo><Affiliation>Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanavivit</LastName><ForeName>Natcha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiso</LastName><ForeName>Apisada</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pongchaikul</LastName><ForeName>Pisut</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirdlarp</LastName><ForeName>Suppachok</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3444-4796</Identifier><AffiliationInfo><Affiliation>Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khemawoot</LastName><ForeName>Phisit</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7994-4503</Identifier><AffiliationInfo><Affiliation>Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nathisuwan</LastName><ForeName>Surakit</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4828-4412</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9035-51-2</RegistryNumber><NameOfSubstance UI="D003577">Cytochrome P-450 Enzyme System</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003577" MajorTopicYN="N">Cytochrome P-450 Enzyme System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004581" MajorTopicYN="N">Electronics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>17</Day><Hour>15</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>16</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37972000</ArticleId><ArticleId IdType="pmc">PMC10653453</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0293866</ArticleId><ArticleId IdType="pii">PONE-D-22-26829</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Origin of SARS-CoV-2 [Internet]. [cited 2022 Aug 13]. https://apps.who.int/iris/bitstream/handle/10665/332197/WHO-2019-nCoV-FAQ-Virus_origin-2020.1-eng.pdf</Citation></Reference><Reference><Citation>World Health Organization WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2023 August 7]. https://covid19.who.int/</Citation></Reference><Reference><Citation>National Health Service. Symptoms of coronavirus (COVID-19) [Internet]. [cited 2022 Aug 13]. https://www.nhs.uk/conditions/coronavirus-covid-19/symptoms/main-symptoms/</Citation></Reference><Reference><Citation>National Health Service. Long-term effects of coronavirus (long COVID) [Internet]. [cited 2022 Aug 13]. https://www.nhs.uk/conditions/coronavirus-covid-19/long-term-effects-of-coronavirus-long-covid/</Citation></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022:jiac136. doi: 10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Centres for Disease Control and Prevention. Long COVID or post-COVID conditions [Internet]. [cited 2022 Aug 13]. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</Citation></Reference><Reference><Citation>Wilson, T. Using Micromedex [Internet]. [cited 2023 July 17]. https://www.ttuhsc.edu/libraries/documents/micromedextwo.pdf</Citation></Reference><Reference><Citation>Drugs.com. The Drugs.com Database [Internet]. [cited 2023 July 17]. https://www.drugs.com/support/about.html</Citation></Reference><Reference><Citation>TrustArc Inc. Drugsite Trust [Internet]. [cited 2023 July 17]. https://privacy.truste.com/privacy-seal/validation?rid=d18cba4a-afc4-4863-af81-8262bb120271</Citation></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159&#x2013;74. doi: 10.2307/2529310</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2529310</ArticleId><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Phichaphop C, Chaichotjinda K, Tansuriyawong P, Kasemsinsup N, Saenghiran B, Sukyotin S, et al.. When pediatricians have to care adult patients with COVID-19: experiences and lessons learned. J Infect Dis Antimicrob Agents. 2020;37:179&#x2013;82.</Citation></Reference><Reference><Citation>Suriyapakorn B, Chairat P, Boonyoprakarn S, Rojanarattanangkul P, Pisetcheep W, Hunsakunachai N, et al.. Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases. PLoS One. 2019;14(11):e0225239. doi: 10.1371/journal.pone.0225239</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0225239</ArticleId><ArticleId IdType="pmc">PMC6855424</ArticleId><ArticleId IdType="pubmed">31725785</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivithanaporn P, Kongratanapasert T, Suriyapakorn B, Songkunlertchai P, Mongkonariyawong P, Limpikirati PK, et al.. Potential drug-drug interactions of antiretrovirals and antimicrobials detected by three databases. Sci Rep. 2021;11(1):6089. doi: 10.1038/s41598-021-85586-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85586-8</ArticleId><ArticleId IdType="pmc">PMC7971054</ArticleId><ArticleId IdType="pubmed">33731842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Zhou K, Misra-Hebert A, Bena J, Kashyap SR. Impact of metabolic syndrome on severity of COVID-19 illness. Metab Syndr Relat Disord. 2022;20(4):191&#x2013;8. doi: 10.1089/met.2021.0102</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/met.2021.0102</ArticleId><ArticleId IdType="pubmed">34995147</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5&#x2013;6):231&#x2013;7. doi: 10.1242/dmm.001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.001180</ArticleId><ArticleId IdType="pmc">PMC2675814</ArticleId><ArticleId IdType="pubmed">19407331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillich FF, Imig JD, Proschak E. Multi-target approaches in metabolic syndrome. Front Pharmacol 2021;11:554961. doi: 10.3389/fphar.2020.554961</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.554961</ArticleId><ArticleId IdType="pmc">PMC7994619</ArticleId><ArticleId IdType="pubmed">33776749</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvergate. Product information: KATERZIA oral suspension, amlodipine oral suspension. Greenwood Village, CO: Silvergate Pharmaceuticals, Inc (per FDA); 2019.</Citation></Reference><Reference><Citation>Farmville N. Product information: NORLIQVA(R) oral solution, amlodipine oral solution. Farmville, NC: CMP Pharma Inc (per FDA); 2022.</Citation></Reference><Reference><Citation>Organon. Product information: ZOCOR(R) oral tablets, simvastatin oral tablets. Jersey City, NJ: Organon &amp; Co (per FDA); 2022.</Citation></Reference><Reference><Citation>Bristol-Myers. Product information: PLAVIX(R) oral tablets, clopidogrel bisulfate oral tablets. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership (per FDA); 2015.</Citation></Reference><Reference><Citation>GlaxoSmithKline. Product information: JALYN(R) oral capsules, dutasteride, tamsulosin HCl oral capsules. Research Triangle Park, NC: GlaxoSmithKline (per FDA); 2017.</Citation></Reference><Reference><Citation>Daveluy A, Raignoux C, Miremont-Salam&#xe9; G, Girodet P-O, Moore N, Haramburu F, et al.. Drug interactions between inhaled corticosteroids and enzymatic inhibitors. Eur J Clin Pharmacol. 2009;65(7):743&#x2013;5. doi: 10.1007/s00228-009-0653-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-009-0653-4</ArticleId><ArticleId IdType="pubmed">19399485</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolhuis MS, Panday PN, Pranger AD, Kosterink JGW, Alffenaar J-WC. Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams. Pharmaceutics. 2011;3(4):865&#x2013;913. doi: 10.3390/pharmaceutics3040865</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics3040865</ArticleId><ArticleId IdType="pmc">PMC3857062</ArticleId><ArticleId IdType="pubmed">24309312</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A, Agarwal S, Kaleekal T, Gupta YK. Rifampicin and anti-hypertensive drugs in chronic kidney disease: pharmacokinetic interactions and their clinical impact. Indian J Nephrol. 2016;26:322. doi: 10.4103/0971-4065.176145</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0971-4065.176145</ArticleId><ArticleId IdType="pmc">PMC5015508</ArticleId><ArticleId IdType="pubmed">27795624</ArticleId></ArticleIdList></Reference><Reference><Citation>Li TY, Liu W, Chen K, Liang SY, Liu F. The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review. J Clin Pharm Ther. 2017;42(2):135&#x2013;46. doi: 10.1111/jcpt.12493</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.12493</ArticleId><ArticleId IdType="pubmed">28177134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallolas J, Sarasa M, Nomdedeu M, Soriano A, L&#xf3;pez-P&#xfa;a Y, Blanco JL, et al.. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med. 2007;8(2):131&#x2013;4. doi: 10.1111/j.1468-1293.2007.00442.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1293.2007.00442.x</ArticleId><ArticleId IdType="pubmed">17352770</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest. 1991;99(2):465&#x2013;71. doi: 10.1378/chest.99.2.465</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.99.2.465</ArticleId><ArticleId IdType="pubmed">1824929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CA, Foisy M, Tseng A. Interactions between antifungal and antiretroviral agents. Expert Opin Drug Saf. 2010;9(5):723&#x2013;42. doi: 10.1517/14740331003752694</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740331003752694</ArticleId><ArticleId IdType="pubmed">20345324</ArticleId></ArticleIdList></Reference><Reference><Citation>Vadlapatla RK, Patel M, Paturi DK, Pal D, Mitra AK. Clinically relevant drug&#x2013;drug interactions between antiretrovirals and antifungals. Expert Opin Drug Metab Toxicol. 2014;10(4):561&#x2013;80. doi: 10.1517/17425255.2014.883379</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425255.2014.883379</ArticleId><ArticleId IdType="pmc">PMC4516223</ArticleId><ArticleId IdType="pubmed">24521092</ArticleId></ArticleIdList></Reference><Reference><Citation>Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020;108(2):242&#x2013;7. doi: 10.1002/cpt.1844</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1844</ArticleId><ArticleId IdType="pubmed">32246834</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung S-H. An overview of severe acute respiratory syndrome&#x2013;coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem. 2016;59(14):6595&#x2013;628. doi: 10.1021/acs.jmedchem.5b01461</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b01461</ArticleId><ArticleId IdType="pmc">PMC7075650</ArticleId><ArticleId IdType="pubmed">26878082</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>